Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 3:57 PM ET

Healthcare Equipment and Supplies

Company Overview of Immucor, Inc.

Company Overview

Immucor Inc. and its subsidiaries develop, manufacture, and sell reagents and automated systems used primarily by hospitals, clinical labs, and blood banks in tests to detect and identify certain properties of the cell and serum components of human blood before blood transfusions. The company’s reagent product lines include abo blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and a fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. These are used in tests to...

3130 Gateway Drive

PO Box 5625

Norcross, GA 30091

United States

Founded in 1982

1,090 Employees





Key Executives for Immucor, Inc.

Chairman of the Board, Chief Executive Officer and President
Age: 52
Chief Financial Officer, Chief Accounting Officer, Vice President and Vice President of International Transfusion Diagnostics
Age: 53
Vice President of Operations
Vice President of International Finance
Age: 58
Compensation as of Fiscal Year 2015.

Immucor, Inc. Key Developments

Immucor, Inc., Q2 2016 Fixed Income Call, Feb 02, 2016

Immucor, Inc., Q2 2016 Fixed Income Call, Feb 02, 2016

Immucor, Inc. and Sirona Genomics Launch MIA FORA NGS HLA Typing Solution

Immucor, Inc. in collaboration with Sirona Genomics announced the launch of MIA FORA NGS, a high resolution HLA typing solution that provides accurate, comprehensive coverage of 11 HLA genes. With an efficient workflow that can be uniquely automated or run manually, MIA FORA NGS is adapted for use on the Illumina MiSeq® next generation sequencing (NGS) platform and is now available research use only (RUO) in the US and other countries, with CE Mark anticipated shortly.

Immucor, Inc. Enters into Amendment to Credit Agreement

On December 9, 2015, Immucor, Inc., IVD Intermediate Holdings B Inc., the Subsidiary Guarantor party thereto, Citibank, N.A., as Administrative Agent, and certain of the various revolving facility lenders party thereto modified the company's senior secured credit facilities by entering into Amendment No. 5 to the credit agreement among the parties dated as of August 19, 2011. The Amendment amends terms relating to the financial covenant on the existing revolving credit facility.

Similar Private Companies By Industry

Company Name Region
InforMedix Holdings Inc. United States
Allard USA Inc. United States
Calcitec, Inc. United States
Medgluv Inc. United States
Advantage Diagnostics Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Immucor, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at